Abbott Laboratories (ABT)
NYSE: ABT · Real-Time Price · USD
125.63
-1.58 (-1.25%)
Mar 25, 2025, 4:00 PM EST - Market closed
Abbott Laboratories Stock Forecast
Stock Price Forecast
The 18 analysts with 12-month price forecasts for Abbott Laboratories stock have an average target of 136.06, with a low estimate of 117 and a high estimate of 160. The average target predicts an increase of 8.31% from the current stock price of 125.63.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Abbott Laboratories stock from 18 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 5 | 5 | 6 |
| Buy | 8 | 8 | 8 | 8 | 8 | 8 |
| Hold | 4 | 4 | 4 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 16 | 16 | 17 | 17 | 18 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Strong Buy Maintains $133 → $150 | Strong Buy | Maintains | $133 → $150 | +19.40% | Mar 10, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $135 → $160 | Strong Buy | Maintains | $135 → $160 | +27.36% | Mar 4, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $138 → $154 | Strong Buy | Maintains | $138 → $154 | +22.59% | Mar 4, 2025 |
| Barclays | Barclays | Buy Maintains $149 → $158 | Buy | Maintains | $149 → $158 | +25.77% | Jan 27, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $135 | Buy | Reiterates | $135 | +7.46% | Jan 23, 2025 |
Financial Forecast
Revenue This Year
44.77B
from 41.95B
Increased by 6.72%
Revenue Next Year
48.11B
from 44.77B
Increased by 7.45%
EPS This Year
5.21
from 7.64
Decreased by -31.85%
EPS Next Year
5.76
from 5.21
Increased by 10.61%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 47.7B | 51.9B | 56.3B | ||
| Avg | 44.8B | 48.1B | 51.6B | ||
| Low | 43.1B | 45.7B | 49.0B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 13.7% | 15.9% | 17.0% | ||
| Avg | 6.7% | 7.5% | 7.4% | ||
| Low | 2.7% | 2.1% | 1.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 5.49 | 6.20 | 6.99 | ||
| Avg | 5.21 | 5.76 | 6.38 | ||
| Low | 4.97 | 5.41 | 5.85 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -28.1% | 19.0% | 21.4% | ||
| Avg | -31.8% | 10.6% | 10.9% | ||
| Low | -35.0% | 3.9% | 1.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.